Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.
This heritage has given the company the experience and capabilities that enable it to help people defeat other serious chronic conditions, such as haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs over 43,000 people and markets its products in more than 170 countries.
Novo Nordisk’s business has been built on the conviction that the formula for lasting success is to think long-term and do business in a financially, socially and environmentally responsible way. As such, Novo Nordisk is one of four companies in the world which have incorporated the Triple Bottom Line principle into its bylaws, in turn guiding the “Novo Nordisk Way” of doing business. As a sustainable business, Novo Nordisk aims to create long-term value for patients, employees, partners and shareholders by developing innovative and competitive solutions to patients’ unmet needs.
As a company that strives to treat diabetes through the sale of insulin as well as educate and raise awareness to eradicate diabetes, Novo Nordisk sees the Benchmark as a key tool to marry these two often competing elements of its business. As one of the founding members of the Development Council, Novo Nordisk has been central to the development of the Future-Fit Business Benchmark and is the first company to fully measure its baseline performance against the Benchmark’s Key Fitness Indicators.